Free Trial

Treace Medical Concepts (TMCI) Competitors

Treace Medical Concepts logo
$6.96 +0.06 (+0.87%)
(As of 12/20/2024 05:16 PM ET)

TMCI vs. RXST, INMD, MDXG, ESTA, BLFS, PLSE, AORT, EMBC, CBLL, and LQDA

Should you be buying Treace Medical Concepts stock or one of its competitors? The main competitors of Treace Medical Concepts include RxSight (RXST), InMode (INMD), MiMedx Group (MDXG), Establishment Labs (ESTA), BioLife Solutions (BLFS), Pulse Biosciences (PLSE), Artivion (AORT), Embecta (EMBC), CeriBell (CBLL), and Liquidia (LQDA). These companies are all part of the "medical equipment" industry.

Treace Medical Concepts vs.

Treace Medical Concepts (NASDAQ:TMCI) and RxSight (NASDAQ:RXST) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, community ranking, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

In the previous week, RxSight had 1 more articles in the media than Treace Medical Concepts. MarketBeat recorded 11 mentions for RxSight and 10 mentions for Treace Medical Concepts. Treace Medical Concepts' average media sentiment score of 0.25 beat RxSight's score of 0.05 indicating that Treace Medical Concepts is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Treace Medical Concepts
2 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
RxSight
2 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

RxSight has a net margin of -23.92% compared to Treace Medical Concepts' net margin of -30.33%. RxSight's return on equity of -14.00% beat Treace Medical Concepts' return on equity.

Company Net Margins Return on Equity Return on Assets
Treace Medical Concepts-30.33% -51.12% -26.36%
RxSight -23.92%-14.00%-12.51%

84.1% of Treace Medical Concepts shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 24.4% of Treace Medical Concepts shares are owned by company insiders. Comparatively, 9.4% of RxSight shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Treace Medical Concepts currently has a consensus price target of $7.88, suggesting a potential upside of 13.22%. RxSight has a consensus price target of $59.00, suggesting a potential upside of 75.28%. Given RxSight's stronger consensus rating and higher probable upside, analysts plainly believe RxSight is more favorable than Treace Medical Concepts.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Treace Medical Concepts
0 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
RxSight
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.75

RxSight has lower revenue, but higher earnings than Treace Medical Concepts. RxSight is trading at a lower price-to-earnings ratio than Treace Medical Concepts, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Treace Medical Concepts$202.86M2.14-$49.53M-$0.99-7.03
RxSight$128.29M10.57-$48.61M-$0.83-40.55

RxSight received 22 more outperform votes than Treace Medical Concepts when rated by MarketBeat users. Likewise, 69.70% of users gave RxSight an outperform vote while only 45.28% of users gave Treace Medical Concepts an outperform vote.

CompanyUnderperformOutperform
Treace Medical ConceptsOutperform Votes
24
45.28%
Underperform Votes
29
54.72%
RxSightOutperform Votes
46
69.70%
Underperform Votes
20
30.30%

Treace Medical Concepts has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, RxSight has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500.

Summary

RxSight beats Treace Medical Concepts on 13 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TMCI vs. The Competition

MetricTreace Medical ConceptsSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$433.59M$4.34B$5.12B$9.07B
Dividend YieldN/A41.46%4.91%4.22%
P/E Ratio-7.0325.3791.3417.19
Price / Sales2.1445.961,117.70116.80
Price / CashN/A43.4542.6437.86
Price / Book3.117.364.794.78
Net Income-$49.53M$13.64M$120.07M$225.60M
7 Day Performance-7.20%-2.80%-1.90%-1.23%
1 Month Performance-12.34%0.56%11.45%3.37%
1 Year Performance-41.41%41.87%30.63%16.58%

Treace Medical Concepts Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TMCI
Treace Medical Concepts
1.7006 of 5 stars
$6.96
+0.9%
$7.88
+13.2%
-36.6%$433.59M$202.86M-7.03250Analyst Forecast
News Coverage
RXST
RxSight
2.9521 of 5 stars
$38.86
+4.2%
$62.13
+59.9%
-11.8%$1.57B$89.08M-46.59220Analyst Downgrade
Gap Down
INMD
InMode
3.6341 of 5 stars
$18.14
-0.7%
$22.60
+24.6%
-21.7%$1.52B$423.75M9.87480Positive News
MDXG
MiMedx Group
2.8123 of 5 stars
$9.45
+3.2%
$12.00
+27.0%
+1.7%$1.39B$342.80M16.65895
ESTA
Establishment Labs
2.5211 of 5 stars
$46.64
+1.4%
$60.60
+29.9%
+73.3%$1.31B$153.07M-17.83960Positive News
BLFS
BioLife Solutions
1.2666 of 5 stars
$27.32
+2.3%
$28.29
+3.5%
+79.4%$1.27B$146.96M-25.19409Analyst Forecast
Insider Trade
News Coverage
PLSE
Pulse Biosciences
1.8256 of 5 stars
$20.32
+15.1%
N/A+56.3%$1.25B$700,000.000.00140Insider Trade
News Coverage
AORT
Artivion
2.2159 of 5 stars
$29.08
+0.5%
$31.80
+9.4%
+59.5%$1.22B$384.90M-1,446.501,500
EMBC
Embecta
3.7712 of 5 stars
$19.87
+1.8%
$23.00
+15.8%
+13.5%$1.16B$1.12B14.712,200Short Interest ↓
CBLL
CeriBell
N/A$29.05
-0.6%
$32.60
+12.2%
N/A$1.04B$60.04M0.00N/A
LQDA
Liquidia
3.4225 of 5 stars
$11.03
+1.0%
$24.00
+117.6%
+3.7%$933.55M$15.61M-6.7050Analyst Forecast
News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:TMCI) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners